AUSTIN, Texas, July 14, 2011 /PRNewswire/ — Convergen
LifeSciences, Inc. announced today that another United
States Patent 7,977,468 has been awarded by the U.S. Patent
and Trademark Office jointly to The University of Texas System
Board of Regents and The Secretary, U.S. Department of Health
and Human Services. The
patent is one of 23 patents, pending or issued worldwide,
licensed exclusively to Convergen LifeSciences, Inc. The patent
covers CNVN202, a targeted molecular cancer therapy
undergoing clinical evaluation in lung cancer patients.
The ‘468 patent is based upon important discoveries made by a
team of researchers from The University of Texas MD
Anderson Cancer Center, The University of Texas
Southwestern Medical Center and the National Cancer
Institute. The discovery of the 3p21.3 family of tumor
suppressor genes has been the subject of more than 20 peer-reviewed
scientific publications demonstrating the genes’ ability to control
key anti-cancer mechanisms. CNVN202 harnesses TUSC2
(FUS1), the most potent inducer of apoptosis among the family
of 3p21.3 cancer suppressor genes.
“The patent further solidifies our growing IP portfolio,” stated
Greg Heinlein, Chief Operating and Financial Officer,
Convergen LifeSciences. “Broadly speaking, this patent
expands the application of CNVN202 to virtually all cancers and
extends the use of our patented technologies to include cancer
diagnostic and screening tools.”
Data from a phase I clinical
‘/>”/>
SOURCE